A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized, controlled, multi-national, multi-center, parallel-arm
trial comparing tivozanib to sorafenib in subjects with advanced RCC. The study is designed
to compare the PFS, OS, ORR, DR, safety and tolerability, and kidney specific symptoms/health
outcome measurements of tivozanib and sorafenib.